NVNO enVVeno Medical Corp
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1661053 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY29.2%
TTM EPS YoY67.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-67.1%
ROA-60.0%
ROIC (approx.)-61.4%
Asset turnover—
Leverage & solvency
Liabilities / assets13.3%
Debt / equity0.00x
Current ratio7.35x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.86x
Accruals ratio-8.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $9.98M | $12.25M | $13.58M | $9.91M | $5.73M |
| SG&A expense | $10.92M | $11.58M | $11.65M | $15.02M | $11.16M |
| Operating income | -$20.90M | -$23.83M | -$25.24M | -$24.93M | -$16.89M |
| Pretax income | -$19.47M | -$21.82M | — | — | — |
| Net income | -$19.47M | -$21.82M | -$23.52M | -$24.67M | -$16.53M |
| EBITDA | -$20.76M | -$23.64M | -$25.02M | -$24.72M | -$16.74M |
| EPS (basic) | -33.06 | -44.53 | -1.91 | -2.20 | -1.90 |
| EPS (diluted) | -33.06 | -44.53 | -1.91 | -2.20 | -1.90 |
| Weighted avg. shares (diluted) | 589,000 | 490,000 | 12.30M | 11.23M | 8.68M |
| Banking | |||||
| Net interest income | — | — | — | $161,000 | $19,000 |
| Balance sheet | |||||
| Cash & equivalents | $3.06M | $1.75M | $3.62M | $4.55M | $54.73M |
| Short-term investments | $25.15M | $41.40M | $42.79M | $34.49M | — |
| Current assets | $28.83M | $43.73M | $46.92M | $39.44M | $55.04M |
| PP&E, net | $51,000 | $182,000 | $334,000 | $521,000 | $618,000 |
| Total assets | $29.56M | $44.95M | $48.63M | $41.66M | $57.70M |
| Current liabilities | $2.12M | $2.10M | $1.37M | $1.53M | $1.58M |
| Total liabilities | $2.43M | $2.79M | $2.44M | $2.93M | $3.29M |
| Shareholders' equity | $27.13M | $42.16M | $46.20M | $38.73M | $54.40M |
| Shares outstanding | 656,000 | 501,000 | 13.32M | 9.47M | 9.47M |
| Cash flow statement | |||||
| Operating cash flow | -$15.57M | -$16.84M | -$18.86M | -$15.62M | -$11.85M |
| Capital expenditure | $5,000 | $37,000 | $33,000 | $115,000 | $368,000 |
| Free cash flow | -$15.57M | -$16.88M | -$18.89M | -$15.73M | -$12.22M |
| Investing cash flow | $15.86M | $1.33M | -$7.87M | -$34.55M | -$368,000 |
| Financing cash flow | $1.02M | $13.64M | $25.79M | — | $57.61M |
| Depreciation & amortization | $136,000 | $189,000 | $220,000 | $212,000 | $149,000 |
| Stock-based compensation | $3.42M | $4.14M | $5.20M | $8.99M | $6.00M |
Free plan shows the latest 5 periods; Pro shows all 9 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.